The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
 
David S. Hong
Research Funding - Daiichi Sankyo; Merck; Millennium; Pharmacyclics
 
Martin Gutierrez
Consulting or Advisory Role - Bayer; Lilly
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Drew W. Rasco
Research Funding - Pharmacyclics
 
Tony R. Reid
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
Research Funding - Genentech
Patents, Royalties, Other Intellectual Property - AIM Specialty Health
Expert Testimony - Novo Nordisk
 
Michael H. Veeder
No Relationships to Disclose
 
Ahmed Tawashi
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie; ANI Pharmaceuticals; Idera; Novartis
Patents, Royalties, Other Intellectual Property - Clinavenir LLC
 
Jennifer Lin
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie
 
Isaiah W. Dimery
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie